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Summary
 
CD4
 
1
 
 T lymphocyte depletion in human immunodeficiency virus type 1 (HIV-1)–infected
humans underlies the development of acquired immune deficiency syndrome. Using a model
in which rhesus macaques were infected with chimeric simian–human immunodeficiency vi-
ruses (SHIVs), we show that both the level of viremia and the structure of the HIV-1 envelope
glycoprotein ectodomains individually contributed to the efficiency with which CD4
 
1
 
 T lym-
phocytes were depleted. The envelope glycoproteins of recombinant SHIVs that efficiently
caused loss of CD4
 
1
 
 T lymphocytes exhibited increased chemokine receptor binding and
membrane-fusing capacity compared with those of less pathogenic viruses. These studies iden-
tify the HIV-1 envelope glycoprotein ectodomains as determinants of CD4
 
1
 
 T lymphocyte
loss in vivo and provide a foundation for studying pathogenic mechanisms.
Key words: simian–human immunodeﬁciency virus • Rhesus macaques • envelope 
glycoprotein • CD4
 
1
 
 T lymphocyte depletion • pathogenesis
 
H
 
uman immunodeficiency virus type 1 (HIV-1) is the
cause of acquired immune deficiency syndrome (AIDS)
 
in humans (1, 2). The related simian immunodeficiency vi-
ruses (SIVs)
 
1
 
 cause AIDS-like illness in Old World monkeys
(3). Acute infection with the primate immunodeficiency
viruses is typically characterized by a high level of viremia
and a transient loss of CD4
 
1
 
 T lymphocytes (4, 5). This
phase of the infection is followed by a reduction in the viral
load and an increase in CD4
 
1
 
 T lymphocytes, sometimes
to near normal levels. In the absence of antiretroviral ther-
apy, a gradual decline in CD4
 
1
 
 T cells and eventual rise in
viremia occurs, ultimately resulting in immunosuppression
in the chronically infected subject. The mechanisms under-
lying the selective depletion of CD4
 
1
 
 T cells during acute
and chronic HIV-1 infection are not well understood. How-
ever, studies of virus and cell turnover in HIV-1–infected
individuals suggest that active viral gene expression is re-
 
1
 
Abbreviations used in this paper:
 
 CAT, chloramphenicol acetyltransferase;
MIP, macrophage inflammatory protein; RT, reverse transcriptase; sCD4,
human soluble CD4; SHIV, simian–human immunodeficiency virus;
SIV, simian immunodeficiency virus.
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quired for the rapid destruction of infected cells (6, 7). Direct
viral cytopathic effects and cytotoxic antiviral immune re-
sponses have been suggested as potential mechanisms for
CD4
 
1
 
 T lymphocyte destruction in HIV-1–infected hu-
mans.
A variety of in vitro cell culture systems have been used
to study HIV-1–induced cytopathic effects, which consist
of the formation of multinucleated giant cells (syncytia) and
the lysis of single cells. The HIV-1 envelope glycoproteins
have been shown to be responsible for both forms of cyto-
pathic effects (8–11). The HIV-1 envelope glycoproteins,
gp120 and gp41, support virus entry by binding to the viral
receptors, CD4, and chemokine receptors on the target cell
(12–20) and by fusing the viral and the target cell mem-
branes. HIV-1 envelope glycoproteins expressed on the in-
fected cell surface fuse these cells with receptor-bearing,
uninfected cells, leading to the formation of lethal syncytia
(8, 9). Intracellular envelope glycoprotein-receptor com-
plexes are capable of mediating membrane fusion reactions
that lead to the lysis of single cells (11).
The identification of HIV-1 genes that are important for
CD4
 
1
 
 T lymphocyte depletion in the infected host could
provide insights into pathogenic mechanisms. Theoreti-
cally, at least two factors contribute to pathogenic outcome
in vivo: virus replication and a property herein called in-
trinsic pathogenicity. Each of these factors could be influ-
enced by viral genetic polymorphism. Adequate levels of
virus replication must be achieved to sustain CD4
 
1
 
 lym-
phocyte depletion in vivo (21–25). Decreases in the repli-
cation of primate immunodeficiency viruses in human or
animal hosts have resulted from genetic alterations in the
virus or host and from antiviral therapy, with a consequent
reduction in the appearance or progression of disease. Since
there are numerous ways by which virus replication can be
reduced (25), identification of viral determinants of replica-
tive ability does not necessarily provide clues to the mecha-
nism of CD4
 
1
 
 T lymphocyte destruction. Intrinsic patho-
genicity describes the ability of a virus to cause pathogenic
consequences at a given level of virus replication. In this
instance, two primate immunodeficiency viruses that differ
in intrinsic pathogenicity would deplete CD4
 
1
 
 T lympho-
cytes to different degrees, even though virus replication is
identical. Genetic alterations in a virus that affect intrinsic
pathogenicity would thus alter the relationship between vi-
rus replication and CD4
 
1
 
 T lymphocyte depletion. The
identification of HIV-1 genetic determinants of intrinsic
pathogenicity should provide clues to the mechanism(s)
underlying CD4
 
1
 
 T cell destruction.
In vivo studies of HIV-1 pathogenesis require suitable
animal models, such as SIV infection of rhesus macaques
(3, 23, 26) and HIV-1 infection of chimpanzees (27). Stud-
ies using rhesus macaques infected with SIV
 
mac
 
239 have
provided several insights into lentivirus pathogenesis, but
this model does not allow an analysis of the role of HIV-
1–encoded gene products. The use of chimpanzees presents
a problem due to the endangered status and expense of
these animals.
 
To study the contribution of HIV-1 genes to in vivo in-
fection and pathogenicity, simian–human immunodeficiency
virus chimeras (SHIVs) have been constructed. SHIVs con-
taining the HIV-1 
 
tat
 
, 
 
rev
 
, 
 
vpu,
 
 and 
 
env
 
 genes in an
SIV
 
mac
 
239 background have been shown to establish persis-
tent infection in a number of Old World monkey species,
including the readily available rhesus macaque (28–31). We
have previously shown that SHIV-89.6, which contains the
envelope glycoproteins of a primary HIV-1 isolate, repli-
cated to high levels in rhesus macaques (32). Despite this
high level of replication, CD4
 
1
 
 T lymphocyte counts re-
mained normal and no disease was induced in the infected
animals. To derive a pathogenic variant of SHIV-89.6, we
subjected the virus to animal-to-animal passage (33). The
resulting virus, SHIV-89.6P, caused rapid and severe de-
pletion of CD4
 
1
 
 T lymphocytes in rhesus macaques within
2 wk after inoculation; furthermore, SHIV-89.6P–infected
animals often exhibited AIDS-like illness within 1 yr of in-
fection (33). Of interest was the observation that the in
vivo viremia in SHIV-89.6P–infected animals during the
first weeks of infection was not dramatically increased com-
pared with that seen in SHIV-89.6–infected animals. This
observation suggested the possibility that animal passage
had resulted in an increase in the intrinsic pathogenicity of
the virus.
To study the genetic basis of the increased pathogenicity
of SHIV-89.6P, molecular proviral clones were obtained
and analyzed. One SHIV-89.6P proviral clone, designated
KB9, generated viruses that caused CD4
 
1
 
 T cell depletion
in all animals inoculated (34). Compared with the parental
SHIV-89.6, SHIV-KB9 contained nucleotide changes in
the LTR and coding changes in the 
 
tat
 
 and 
 
env
 
 genes (34).
Some of the 
 
env
 
 changes resulted in single amino acid
changes in the gp120 and gp41 envelope glycoprotein
ectodomains. In addition, a large 
 
env
 
 deletion resulted in a
gp41 cytoplasmic tail containing elements of both HIV-1
and SIV gp41 cytoplasmic domains (34).
The availability of molecularly cloned nonpathogenic
and pathogenic SHIVs presents an ideal opportunity to
identify HIV-1 determinants of rapid CD4
 
1
 
 lymphocyte
depletion in a setting where potentially confounding, spe-
cific antiviral immune responses are minimal. Here, chime-
ras between SHIV-89.6 and SHIV-KB9 were evaluated in
rhesus monkeys for replication and in vivo CD4
 
1
 
 T cell–
depleting ability during acute infection. Viral genetic deter-
minants of replication and intrinsic pathogenicity were in-
dependently defined, and in vitro phenotypes associated
with the identified segments were characterized.
 
Materials and Methods
 
Cells and Viruses.
 
Ficoll-enriched rhesus PBMCs were stimu-
lated with 1 
 
m
 
g/ml phytohemagglutinin (Murex Diagnostics Ltd.,
Dartfield, UK) for 48–72 h and incubated with human IL-2 (10%
IL-2; Hemagen Diagnostics Inc., Columbia, MD) beginning 24 h
before infection. Rhesus macrophages were cultured as previ-
ously described (35). 
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The molecularly cloned parental virus, SHIV-89.6, and the in
vivo–passaged variant, SHIV-KB9, have been described else-
where (32, 34). Infectious virus was produced by ligation of the
SphI-digested 5
 
9
 
 and 3
 
9
 
 proviral halves, followed by transfection
of CEM
 
3
 
174 cells, as described previously (28). For this study,
three additional 3
 
9
 
 proviral halves were constructed as follows.
For the
 
 
 
KB9ct 3
 
9
 
 proviral plasmid, the KpnI–XhoI fragment of
SHIV-89.6 was cloned into the KB9 3
 
9
 
 proviral plasmid. For the
89.6
 
*
 
 3
 
9
 
 proviral plasmid, the KpnI–NcoI fragment of SHIV-89.6
was cloned into the KB9 3
 
9
 
 proviral plasmid to produce the LT
plasmid. Then the KpnI–BamHI fragment of KB9ct was cloned
into LT. For the KB9ecto 3
 
9
 
 proviral plasmid, the KpnI–BamHI
fragment of KB9 was cloned into the 89.6
 
*
 
 3
 
9
 
 proviral plasmid.
For generation of infectious SHIV-89.6 virus, the SHIV-89.6 3
 
9
 
half was ligated to the SIV
 
mac
 
239 wt 5
 
9
 
 half. For the 89.6
 
*
 
, KB9ct,
KB9ecto, and KB9 viruses, the appropriate 3
 
9
 
 proviral halves
were ligated to the SIV
 
mac
 
239R 5
 
9
 
 proviral half. The SIV
 
mac
 
239R
5
 
9
 
 proviral half contains a single passage-associated nucleotide
change in the R region of the LTR when compared with the
SIV
 
mac
 
239 5
 
9
 
 proviral clone (34). Virus-containing supernatants
from transfected CEM
 
3
 
174 cells were normalized according to
reverse transcriptase (RT) activity and frozen for subsequent in
vitro and in vivo infections.
 
Animal Inoculations.
 
Rhesus monkeys (Macaca mulatta) were
inoculated intravenously with SHIV-KB9, SHIV-KB9ct, SHIV-
KB9ecto, and SHIV-89.6
 
*
 
 viruses using supernatants from trans-
fected CEM
 
3
 
174 cells normalized for equivalent RT activity.
The supernatants were harvested at peak replication in the
CEM
 
3
 
174 culture and 1 ml of supernatant, 
 
z
 
10
 
6
 
 RT units, was
used in each inoculation. The rhesus monkeys used in this study
were maintained in accordance with the guidelines of the Com-
mittee on Animals for the Harvard Medical School and the 
 
Guide
for the Care and Use of Laboratory Animals
 
 (NIH 85-23). Monkeys
were anesthetized with ketamine-HCl for all blood sampling and
inoculations, and with Telazol for biopsies.
 
Flow Cytometry.
 
Peripheral blood lymphocytes obtained from
the infected animals were phenotyped for CD3/CD4 and CD3/
CD8, as previously described (36). Absolute lymphocyte counts
in blood were determined on an automated hematology analyzer
(T540; Coulter Corp., Hialeah, FL) that provided a partial differ-
ential count.
 
SIV
 
mac
 
 p27 Assay.
 
The concentration of SIV
 
mac
 
 p27 core an-
tigen in heparinized plasma from SHIV-infected animals, or from
rhesus macrophage cultures infected in vitro
 
,
 
 was determined by
using a commercial kit (SIV Core [p27] Antigen EIA kit; Coulter
Corp.).
 
Plasma Viral RNA Quantitation.
 
Quantitative assays for the
measurement of SHIV RNA were performed by Chiron Corp.
(Emeryville, CA), using a branched DNA signal amplification as-
say for the SIV 
 
pol
 
 region similar to the Quantiplex HIV-RNA
branched DNA assay (37). The assay results were quantified by
comparison with purified and quantitated in vitro–transcribed SIV
 
pol RNA.
In Situ Hybridization for SHIV RNA in Lymph Nodes. In situ
hybridization of lymph nodes obtained on days 10 and 21 after
virus inoculation was performed, using two previously described
permeabilization procedures (26, 38). Cells with at least 20 silver
grains, which corresponded to a sixfold increase in silver grains
over the background level, were scored as viral RNA–positive.
By using epiluminescent illumination, viral RNA–positive cells
in 10 standard areas (450 3 700 mm) of the T cell–dependent
zones of the lymph nodes were counted with an 320 objective
and the means were calculated.
Immunohistochemistry of Lymph Node Sections. Pieces of lymph
nodes were embedded in OCT compound medium and snap-
frozen in liquid nitrogen. Cryostat sections were cut under
RNase-free conditions, fixed in 100% acetone for 30 min, and
stored at 2708C until use. Before immunohistochemistry, the
sections were postfixed in 2% paraformaldehyde (15 min at room
temperature), washed in PBS, and incubated either with a pool of
CD4 antibodies consisting of 3 ml Leu3a (Becton Dickinson,
Heidelberg, Germany), 7.5 ml OKT4 (Ortho Diagnostic System,
Neckargemünd, Germany), and 3.5 ml NCL CD4-1F6 (Newcas-
tle-upon-Tyne, UK) or with Dako-CD68 (1:70 dilution; Dako-
patts, Copenhagen, Denmark) for macrophages. Binding of primary
antibodies was visualized by the alkaline phosphatase/anti–alka-
line phosphatase technique using New Fuchsin as chromogen,
and the sections were subjected to in situ hybridization to detect
SIV RNA. The hybridizations on the frozen sections were per-
formed as described above, with the exception that the permeabi-
lization procedure was omitted and the exposure time was shorter
(3 d at 48C).
Statistics. The goal of the statistical analysis was to identify
plausible models for describing the role of viral replication and vi-
ral genetic determinants as predictors of CD41 T cell depletion
during the acute infection. As a measure of viral replication, the
cumulative p27 antigenemia for days 0–21 was derived by esti-
mating the area under the p27 versus time curve using the trape-
zoidal method. As a measure of CD41 T lymphocyte levels, the
median value of the absolute peripheral blood CD41 T cell
counts recorded from day 14 to 36 after inoculation was calcu-
lated. A two-by-two factorial design characterized the experi-
ment. Two animals had cumulative p27 values below detectable
limits (these animals were confirmed to be infected by their se-
ropositivity). These animals were considered ineligible and were
omitted from the analysis. Partial F tests were used to compare
nested models within the same family. Because each animal’s
measurements were used in two models of CD41 T lymphocyte
counts and cumulative antigenemia, a Bonferroni correction was
made to the type I error, and a two-sided significance level of
0.025 was used. The adjusted R2 statistic was used to characterize
the proportion of variability explained by each model (39).
Plasmids Expressing Envelope Glycoproteins. The pSVIIIenv plas-
mid expressing the HIV-1 89.6 envelope glycoproteins has been
described elsewhere (40). An envelope expressor plasmid, desig-
nated pSVIIIenv-89.6tail, containing the modified COOH ter-
minus of the KB9 gp41 envelope glycoprotein, was constructed
using the BamHI–NcoI (blunted) fragment of KB9 cloned into
the BamHI–XhoI (blunted)–digested pSVIIIenv-89.6 plasmid.
The KpnI–BamI fragment of the 39 proviral halves was cloned
into  pSVIIIenv-89.6tail (KB9, KB9ct) or into pSVIIIenv-89.6
(KB9ecto) to create the corresponding envelope expressor plas-
mids. These were designated: pSVIIIenv-KB9, pSVIIIenv-KB9ct,
and pSVIIIenv-KB9ecto. For expression of gp120 in Drosophila
Schneider 2 cells, sequences encoding the 89.6 and KB9 gp120
were PCR amplified and cloned into the pMt vector (41), intro-
ducing a stop codon that terminated the protein at the natural
gp120/gp41 proteolytic cleavage site. The gp120 glycoproteins
were produced and purified from stably transfected Drosophila
cells, as previously described (19, 41).
In Vitro Infections. Equivalent amounts (50,000 RT units) of
virus from transfected CEM3174 cells were added to 3 3 106
cells (for CEM3174 and PBMCs) or to each well (for macro-
phages) and incubated overnight. The virus was washed out 1 d
after the infection and cultures were monitored for RT activity
or p27 production for the duration of the experiment.1162 Envelope Glycoprotein Determinants of CD41 T Cell Loss
Syncytium Formation Assays. COS-1 cells were cotransfected
with the pSVIIIenv plasmids and with a plasmid expressing the
HIV-1 Tat protein. A portion of the cells was used to control for
envelope glycoprotein expression by labeling with [35S]cysteine
overnight and precipitating the cell lysates with serum from an
HIV-1–infected individual. For the syncytium formation assays,
envelope glycoprotein-expressing COS-1 cells were detached us-
ing 50 mM EDTA in PBS and plated at 150,000 cells/well (in 0.5
ml RPMI 1640 plus FBS) with 1.5 3 106 target CEM3174 cells
(in 0.5 ml RPMI 1640 plus FBS) in duplicate in 48-well plates.
Wells were scored for syncytia after 6 h of cocultivation at 378C.
ELISA for Binding of Human Soluble CD4 to Monomeric
gp120. 96-well plates were coated with 100 ng per well of hu-
man soluble (s)CD4 in 100 ml of 100 mM sodium carbonate/bi-
carbonate buffer, pH 9.6. Plates were incubated at 48C for 24 h,
washed five times with PBS containing 0.2% Tween (PBS/
Tween), and incubated an additional 24 h at 48C with 300 ml
blocking buffer (PBS containing 2% nonfat dried milk and 5%
heat inactivated FBS). After removal of the blocking buffer, the
plates were incubated for 1 h at room temperature with twofold
serial dilutions of 89.6 or KB9 gp120 envelope glycoprotein in
PBS/Tween, starting at a concentration of 9.4 3 1028 M in a to-
tal volume of 100 ml. Plates were washed 10 times and incubated
for 1 h at room temperature with primary antibody (rabbit anti-
DV1/V2/V3 serum, pool III, diluted 1:1,000 in blocking buffer
(Wyatt, R., unpublished observations). The plates were washed
and incubated with anti–rabbit biotin (Amersham Biotech, Ar-
lington Heights, IL), diluted 1:2,000 in blocking buffer overnight
at 48C. This was followed by washes and incubation with strepta-
vidin–horseradish peroxidase (Pierce Chemical Co., Rockford, IL),
diluted 1:2,000 in PBS/Tween for 30 min at room temperature.
Plates were washed and incubated with 100 ml/well TMB substrate
(Bio-Rad, Hercules, CA) and the reaction was stopped with 100
ml 180 mM HCl per well. The plates were read at 450 nm.
Binding of Human and Rhesus sCD4 to Oligomeric Envelope Gly-
coproteins. COS-1 cells were transfected with pSVIIIenv-89.6,
pSVIIIenv-KB9, or pSVIIIenv-368 D/R as described above. The
pSVIIIenv-368 D/R plasmid encodes an HIV-1 envelope glyco-
protein that is defective for CD4 binding (42) and was included
in these experiments as a control for nonspecific binding. The en-
velope glycoprotein surface expression was analyzed by incubation
of cells with serum from an HIV-1–infected individual, followed
by washing, cell lysis, and precipitation with protein A–Sepharose.
For the sCD4 binding assays, supernatants containing metaboli-
cally labeled human or rhesus soluble CD4 were produced in
COS-1 cells and incubated with envelope glycoprotein–express-
ing cells. After washing, bound and unbound sCD4 were immu-
noprecipitated from lysed cells or supernatants, respectively, using
a polyclonal antiserum against CD4.
Env Complementation Assay and Analysis of Coreceptor Usage.
Approximately 10,000 RT units of recombinant HIV-1 virions
containing the different HIV-1 envelope glycoproteins were pro-
duced in COS-1 cells and incubated for 3 h at 378C with Cf2Th
cells expressing human or rhesus CD4 and chemokine receptors,
as previously described (16).
Chemokine Receptor–binding Experiments. Binding of 89.6 and
KB9 gp120 to human CCR5 was analyzed using L1.2 cells stably
expressing human CCR5. Relative binding constants for the
gp120 glycoproteins were determined by incubating iodinated
macrophage inflammatory protein (MIP)-1b with the CCR5-
L1.2 cells in the presence of increasing concentrations of unla-
beled envelope glycoprotein competitor, as previously described
(19). The YU2D1/2/3 glycoprotein was included as a negative
control in the competition experiments (30), and unlabeled MIP-
1b (R&D Systems, Minneapolis, MN) was included as a positive
control.
Neutralization Assays with Antibodies, sCD4, or Plasma. COS-1
cell supernatants containing recombinant virions (5,000 RT
units) expressing different envelope glycoproteins were incubated
with increasing concentrations of antibodies or sCD4 for 1 h at
378C before the addition of CEM3174 cells. Medium was added
1 d after infection and cultures were incubated another 48 h be-
fore harvesting and analysis. Plasma samples obtained from in-
fected animals were heat-inactivated for 15 min at 558C and used
at a 1:50 dilution for neutralization experiments.
Seroconversion. Cell lysates from radiolabeled COS-1 cells
transfected with pSVIIIenv-89.6, pSVIIIenv-KB9ct, pSVIIIenv-
KB9ecto, and pSVIIIenv-KB9 were immunoprecipitated with 8
ml heat-inactivated plasma from infected animals obtained at dif-
ferent time points after virus inoculation. Emergence of antibod-
ies recognizing the homologous envelope glycoproteins was de-
tected by SDS-PAGE and autoradiography.
SHIV-specific Cytotoxic Effector Cell Responses. Virus-specific cy-
tolytic effector cell activity was determined as previously de-
scribed (43), using autologous B lymphoblastic target cells in-
fected with recombinant vaccinia viruses expressing the HIV-1
89.6 envelope glycoproteins (Dr. Dennis Panicali, Therion Bio-
logics Corporation, Cambridge, MA).
Results
CD41 T lymphocyte Counts and Viral Replication in Mon-
keys Infected with SHIV Variants. To examine the role of
specific envelope glycoprotein determinants in the rapid
CD41 T lymphocyte depletion seen in SHIV-KB9–infected
monkeys, the in vivo replication and CD41 T cell-deplet-
ing ability of four SHIV variants were studied. The starting
virus for these studies was SHIV-89.6*, which contains
only the passage-associated LTR and tat changes compared
with the nonpathogenic SHIV-89.6 virus. The other three
SHIV variants differed from SHIV-89.6* only in the se-
quences of the envelope glycoproteins (Fig. 1). SHIV-KB9
has both the passage-associated single amino acid changes
in the gp120/gp41 ectodomains and the gp41 cytoplasmic
tail change compared with SHIV-89.6*. SHIV-KB9ecto
has only the ectodomain changes, whereas SHIV-KB9ct
has only the gp41 cytoplasmic tail change.
A total of 28 monkeys (7 with each of the four SHIV
variants) were inoculated intravenously with virus. The ab-
solute numbers of CD41 and CD81 T lymphocytes and
CD201 B lymphocytes in the peripheral blood were deter-
mined at regular intervals after infection. As has been previ-
ously observed in SIV- and SHIV-infected monkeys (26,
33), most of the animals exhibited a transient, modest lym-
phopenia that involved all of the lymphocyte subsets exam-
ined (data not shown). Between wk 1 and 2 after infection,
the CD81 T lymphocyte and CD201 B lymphocyte counts
returned to normal levels. The CD41 T lymphocyte
counts exhibited different patterns, depending upon the in-
fecting SHIV (Fig. 2 A). Consistent with previously pub-
lished results (34), all monkeys inoculated with SHIV-KB9
exhibited severely depressed CD41 lymphocyte levels,1163 Karlsson et al.
ranging from 30 to 220 cells per ml of blood by 14 d after
infection. Animals inoculated with SHIV-89.6* showed no
persistent loss of CD41 T cells, indicating that the passage-
associated tat and LTR changes are not sufficient to cause
CD41 T lymphocyte depletion. Inoculation with SHIV-
KB9ct resulted in variable levels of CD41 T cell depletion:
three out of seven animals (13898, 18390, and 15655)
maintained normal CD41 T cell levels; moderate depletion
was observed in two animals (15865 and 18284); and more
severe depletion was seen in two animals (11796 and
13939). Inoculation with SHIV-KB9ecto resulted in less
variability; all animals except two (14122 and 15669) ex-
hibited severe CD41 T cell depletion within 14 d of infec-
tion.
To examine the in vivo replicative abilities of the four
SHIV variants, the level of plasma p27 antigenemia during
acute infection was examined (Fig. 2 B). The animals infected
with SHIV-89.6* exhibited the lowest levels of replication
(,0.55 ng/ml at peak viremia), whereas peak viremia in
the SHIV-KB9ct-, SHIV-KB9ecto-, and SHIV-KB9-infected
animals ranged between 0.3 and 6.0 ng/ml, 0.11 and 4.0
ng/ml, and 0.78 and 10.0 ng/ml, respectively. In 16 of the
animals (4 from each group), the level of viremia on day 10
after infection was confirmed by measurement of plasma
viral RNA. The latter values correlated almost precisely with
those obtained using the p27 assay (Spearman r 5 0.98, P ,
0.0001).
The relationship between virus replication and CD41 T
lymphocyte depletion was examined. Within a group of
monkeys infected with the same virus, the observed levels
of replication helped to explain the degree of CD41 T
lymphocyte decline in the monkeys. For example, among
the monkeys infected with SHIV-KB9ct, the two animals
(11796 and 13939) that exhibited the most severe depletion
of CD41 T cells also exhibited the highest levels of replica-
tion. In the group infected with SHIV-KB9ecto, the two
monkeys (14122 and 15669) that maintained normal CD41
Figure 1. Genomic organization of SHIV variants. The SHIV proviral
genome is shown on the top. Sequences from SIVmac239 are shown in
gray boxes and sequences from HIV-1 are shown in white (47, 52). En-
zyme restriction sites relevant for cloning of the SHIV variants are shown.
The proviral structures of the SHIV variants used in this study are
depicted beneath. SHIV-89.6* is identical to the parental SHIV-89.6, ex-
cept that it contains the passage-associated tat and LTR changes (34). The
other three variants differ from SHIV-89.6* only in the sequence of the
envelope glycoproteins. SHIV-KB9 has the passage-associated amino acid
changes in the gp120/gp41 ectodomains and the gp41 cytoplasmic tail
change compared with SHIV-89.6*. SHIV-KB9ct has only the gp41 cy-
toplasmic tail change, and SHIV-KB9ecto has only the gp120/gp41
ectodomain changes.
Figure 2. Absolute CD41 T cell counts and plasma p27 antigenemia in infected monkeys. (A) The absolute CD41 T cell counts in the peripheral
blood of animals infected with SHIV-89.6*, SHIV-KB9ct, SHIV-KB9ecto, and SHIV-KB9 during the first 36 d of infection are shown. (B) The p27 an-
tigen levels in the plasma of SHIV-infected animals are shown.1164 Envelope Glycoprotein Determinants of CD41 T Cell Loss
lymphocyte counts exhibited the lowest levels of replica-
tion. However, CD4 depletion in monkeys infected with
different viruses often could not be explained simply by ac-
counting for the level of virus replication. For example, all
of the animals inoculated with SHIV-KB9 exhibited severe
CD41 T cell depletion, even those monkeys (13921, 15823,
and 13950) in which the peak level of viremia was rela-
tively low (between 0.5 and 2 ng/ml on day 10). Several
animals (13916, 13945, 16155, and 15487) with low CD41
T cell counts and low levels of replication were also present
in the SHIV-KB9ecto group. In contrast, the animals in
the SHIV-KB9ct group that replicated the virus in this
range (animals 15865, 18390, 18284, and 15655) did not
exhibit severe loss of CD41 T cells. These data suggested
the possibility that viruses with the KB9 envelope glyco-
protein ectodomains might deplete CD41 T cells more ef-
ficiently than a comparable number of viruses lacking the
passage-associated changes in the envelope glycoprotein
ectodomains.
The hypothesis that specific env determinants equip the
SHIV variants with different intrinsic pathogenicity (i.e.,
the ability to deplete CD41 T lymphocytes) was tested us-
ing statistical analysis. The contributions of the two viral
envelope glycoprotein determinants, the ectodomain changes
and the cytoplasmic tail change, were analyzed. To this
end, several plausible models were investigated. These in-
cluded a nonlinear exponential decay model with three co-
variates, a linear transformation of the exponential decay
model, an inverse model, and a nonlinear hyperbolic model.
Based on the F statistics, which describe goodness of fit,
and the adjusted R2 value, which represents the proportion
of variability in CD41 T lymphocyte levels explained by
the model, a nonlinear exponential decay model with pa-
rameters for cumulative p27 antigenemia, envelope glyco-
protein changes (yes/no), and the interaction between cu-
mulative p27 antigenemia and envelope glycoprotein changes
was selected as “best”. Although extensive examination of
residuals could not be undertaken due to the small sample
size, a visual assessment of residuals did not reveal serious
violations of model assumptions. The relationship between
cumulative p27 antigenemia and CD41 T lymphocyte
counts for viruses that differ in either envelope glycopro-
tein ectodomain or cytoplasmic tail sequences is shown in
Fig. 3, panels A and B, respectively. The curves shown are
based on a nonlinear exponential decay model. Partial F
tests revealed that ectodomain changes and their associated
interaction contributed significantly to the model’s explan-
atory power (P , 0.001), whereas the passage-associated
cytoplasmic tail modification did not (P 5 0.0532). Thus,
for a given level of antigenemia, viruses with KB9 enve-
lope glycoprotein ectodomains deplete CD41 T lympho-
cytes more efficiently than viruses with wild-type 89.6
ectodomain sequences. In contrast, the KB9 cytoplasmic
tail does not contribute to the intrinsic ability of the viruses
to cause CD41 T cell decline. Thus, although the presence
of KB9 sequences in both envelope glycoprotein domains
contributes to an increase in virus replication in vivo, only
the passage-associated ectodomain changes increase the ef-
ficiency with which CD41 T lymphocytes are depleted.
Analysis of Virus-infected Cells in Lymph Nodes. Previous
studies demonstrated that at the peak of viremia in mon-
keys acutely infected by SIV or SHIV a large number of
cells expressing viral RNA are present in the T cell–depen-
dent areas of the lymph nodes (26, 32). This number di-
minishes rapidly so that by day 21 after infection, when the
viremia has cleared, only a few infected cells can be identi-
fied in lymphoid organs. To examine the lymphatic tissues
in the monkeys infected with the SHIV variants, lymph
node sections obtained at days 10 and 21 after infection
were probed for viral RNA expression by in situ hybridiza-
tion. These studies focused on the T cell–dependent zones
in the lymph nodes, since these areas harbor the majority of
potentially infectable T lymphocytes. As was previously seen
for SIV- or SHIV-infected monkeys (26, 32), the number
Figure 3. Relationship between viremia and CD41 T lymphocyte
counts for SHIV variants with different envelope glycoprotein domains.
A “set-point” value for the absolute CD41 T lymphocyte count in each
animal (the median of the CD4 counts recorded on days 14–36 after in-
fection) was plotted against the cumulative p27 antigenemia (area under
the p27 versus time curves in Fig. 2 B). The data were grouped according
to the sequences (either wild-type 89.6 or containing the KB9 passage-
associated changes) of the viral envelope glycoprotein ectodomains (A) or
cytoplasmic tails (B). The curves are fitted to the data using a nonlinear
exponential decay model.
Figure 4. Relationship between infected lymph node cells and CD41
T lymphocyte counts. The number of viral RNA–positive cells in the T
cell zone of lymph nodes, which were taken from the animals at day 10
after inoculation, was compared with the “set point” values for the pe-
ripheral blood CD41 T lymphocyte counts. The animal identification
numbers for three of the data points discussed in the text are provided.1165 Karlsson et al.
of viral RNA–positive cells was significantly higher on day
10 than on day 21 for all of the SHIV variants (data not
shown). Fig. 4 shows that there was a strong inverse corre-
lation between the number of viral RNA–positive cells in
the lymph nodes at day 10 and the peripheral blood CD41
T lymphocyte counts. These results suggest that the lymph
node sections sampled in this study were reasonably repre-
sentative, and that CD41 T lymphocyte depletion in this
model is strongly influenced by the number of infected
cells in the lymphoid organs.
The number of CD41 cells in the T cell–dependent
zones of the lymph nodes from infected monkeys was de-
termined by immunohistochemistry. There was a very
strong correlation (Spearman r 5 0.87, P , 0.001) between
the number of CD41 cells in the lymph node sections and
the peripheral blood CD41 lymphocyte counts at day 21
(data not shown). This observation is consistent with stud-
ies demonstrating that by day 14 after infection with un-
cloned SHIV-89.6P, CD41 lymphocytes were depleted in
all of the lymphoid organs examined at necropsy (Rei-
mann, K., and N. Letvin, unpublished observations).
By combining immunohistochemistry with in situ hy-
bridization for viral RNA, we attempted to estimate the
percentage of virus-infected CD41 cells in the lymph nodes
of two SHIV-KB9–infected monkeys, animals 13921 and
13970 (Table 1). In both animals, the number of viral
RNA-positive cells in a lymph node section was higher on
day 10 after infection than on day 21. Some of the viral
RNA–positive cells were CD42 and probably represent
cells that had intrinsically low levels of CD4 expression or
that had downregulated CD4 after infection. A technical
limitation of the methodology is that, when viral RNA sig-
nals are very high, definitive assignment of the cell to either
the CD41 or CD42 subset is not possible. Even if one as-
sumes that these uncharacterized cells were CD41, only
z4–5% of the CD41 cells in the lymph node of monkey
13921 were viral RNA-positive 10 d after infection. By
day 21, a continued decrease in the number of CD41 cells
in the T cell–dependent region of the lymph node was ob-
served, and the percentage of CD41 cells that were viral
RNA–positive decreased to 0.4%. In monkey 13970, the
number of CD41 cells in the lymph nodes was only 10% of
that seen in uninfected animals by day 10 after infection,
and declined even further by day 21. Assuming that all of
the cells with extremely high viral RNA signals were
CD41, up to 19% of the CD41 cells in the lymph node
section were viral RNA–positive at day 10 after infection.
This value decreased to ,3% by day 21 after infection.
Thus, a minority of CD41 cells in the lymph nodes of
SHIV-KB9–infected animals were detectably viral RNA-
positive at the time points examined, even when CD41
lymphocyte depletion was extensive.
Infectivity and Syncytium-forming Ability of SHIV Variants.
The in vitro replicative abilities of the SHIV variants were
examined in primary rhesus monkey PBMCs and mac-
rophages. SHIV-KB9 exhibited the most efficient replica-
tion in activated PBMC, closely followed by SHIV-
KB9ecto (Fig. 5 A). SHIV-KB9ct showed increased levels
of replication compared with the parental SHIV-89.6 and
SHIV-89.6*, which replicated with identical efficiencies.
The SHIV-KB9ct virus replicated less efficiently than ei-
ther SHIV-KB9 or SHIV-KB9ecto. Thus, changes in both
the gp120/gp41 ectodomains and the gp41 cytoplasmic
domain of the passaged virus contribute to the increased
replication of KB9 in cultured rhesus PBMCs. When the
ability of the SHIV variants to replicate in rhesus macro-
phages was assessed, a modest increase was observed for
SHIV-KB9 and SHIV-KB9ecto compared with the other
variants. However, these levels of replication were barely
detectable and were z10-fold lower than that observed for
SIVmac316, a macrophage-tropic SIV included in the ex-
periments as a positive control (data not shown).
The replication of the SHIV variants in a human cell
line, CEM3174, was also examined. Interestingly, SHIV-
KB9 did not exhibit a replication advantage in this cell line
(data not shown). In fact, the parental SHIV-89.6 repli-
cated more efficiently than the other variants in CEM3174
cells. Apparently some of the replication phenotypes associ-
ated with the changes in SHIV-KB9 are influenced by host
cell type. A consistent and striking increase in the number
Table 1. Expression of Viral RNA and CD4 in Cells in the T Cell–dependent Zone of Lymph Nodes
Animal Days after infection Total CD41 cells
CD41 viral 
RNA1 cells
CD42 viral
RNA1 cells
Uncharacterized
cells with very
high viral RNA
13921 10 267 (206–311) 10.8 (8–16) 1.8 (1–2) 1.0 (0–2)
21 120 (93–154) 0.5 (0–1) 0.5 (0–1) 0
13970 10 38 (13–82) 2.0 (1–3) 9.5 (6–14) 5 (1–8)
21 17 (9–27) 0.4 (0–1) 1.4 (0–3) 0
Uninfected control – 409 (381–447) ND ND ND
Uninfected control – 386 (349–421) ND ND ND
The number of cells positive for viral RNA or CD4 expression in a standard field is reported. The numbers in parentheses represent the range of val-
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and size of syncytia was seen in the cultures infected with
SHIV-KB9 and SHIV-KB9ecto, even when compared with
cultures infected with the more efficiently replicating
SHIV-89.6 (Fig. 5 B). In contrast, the syncytia in cultures
infected with SHIV-89.6* and SHIV-KB9ct were similar
in appearance to those in the SHIV-89.6-infected cells
(data not shown). These observations suggested that the
syncytium-forming ability of the viruses with the KB9 en-
velope glycoprotein ectodomains might be better than that
of viruses with wild-type 89.6 ectodomains.
To analyze the fusogenic activity of the envelope glyco-
proteins in a more controlled fashion, syncytium forma-
tion assays were performed by cocultivation of COS-1 cells
expressing the viral envelope glycoproteins with target
CEM3174 cells. All of the envelope glycoproteins exhib-
ited comparable processing of the gp160 envelope glyco-
protein precursor, gp120-gp41 association and cell surface
expression in transfected COS-1 cells (data not shown).
Both the KB9 and KB9ecto envelope glycoproteins in-
duced the formation of syncytia with approximately five-
fold higher efficiency than the parental 89.6 envelope gly-
coproteins (Fig. 5 C). The KB9ct envelope glycoproteins
mediated syncytium formation at an efficiency comparable
to that seen for the 89.6 envelope glycoproteins. Thus, the
KB9 envelope glycoprotein ectodomain sequences specify
an increased fusogenic capacity.
Receptor Binding of Envelope Glycoproteins of SHIV Vari-
ants. Two different assays were used to determine whether
the KB9 envelope glycoproteins bind CD4 more efficiently
than do the parental 89.6 envelope glycoproteins. First,
binding of the monomeric gp120 envelope glycoproteins
to sCD4 was compared using an ELISA. In brief, sCD4
was coated onto the ELISA plate and serially diluted 89.6
or KB9 gp120 was bound to the CD4, followed by detec-
tion with an anti-gp120 rabbit serum. The two gp120 gly-
coproteins bound sCD4 with comparable affinity (Fig. 6 A).
To analyze the interaction of soluble CD4 with the oligo-
meric 89.6 and KB9 envelope glycoproteins, binding of
metabolically labeled sCD4 to cells expressing the envelope
glycoproteins was performed. In this assay, both human
and rhesus monkey soluble CD4 bound the oligomeric
89.6 and KB9 envelope glycoproteins with similar affinity
(data not shown). Thus, neither a generic increase in CD4-
binding affinity nor a specific adaptation to rhesus CD4 ap-
pears to account for the enhanced fusogenic activity of the
KB9 envelope glycoproteins.
To assess whether SHIV-KB9 exhibited an altered ability,
either qualitative or quantitative, to initiate infection via hu-
man and rhesus chemokine receptors, compared with SHIV-
89.6, an env-complementation assay (16) was used. Re-
combinant HIV-1 viruses were produced by cotransfecting
COS-1 cells with two plasmids, pHXBH10DenvCAT and
pSVIIIenv. The pHXBH10DenvCAT plasmid contains an
env-defective HIV-1 provirus that encodes chlorampheni-
col acetyltransferase (CAT); the pSVIIIenv plasmids encode
either the 89.6 or KB9 envelope glycoproteins. Virus-con-
taining COS-1 supernatants were normalized for RT activ-
ity and used for infection of Cf2Th canine thymocytes
Figure 5. Replication and syncytium-forming ability of SHIV variants.
(A) Rhesus PBMCs were PHA-stimulated and infected with equal
amounts of SHIV-89.6, SHIV-89.6*, SHIV-KB9ct, SHIV-KB9ecto, and
SHIV-KB9. Cells were maintained in the presence of IL-2 for the dura-
tion of the experiment and an aliquot of the culture medium was re-
moved every day for RT analysis. (B) Uninfected CEM3174 cultures
(mock) were compared with cultures infected with SHIV-89.6, SHIV-
KB9ecto, and SHIV-KB9 for the presence of syncytia. (C) COS-1 cells,
transiently expressing the 89.6, KB9ct, KB9ecto, or KB9 envelope glyco-
proteins, were cocultivated with CEM3174 cells for 6 h at 378C. The
number of syncytia was scored and normalized to that observed for the
parental 89.6 envelope glycoproteins. The mean values and SE derived
from three independent experiments are shown.1167 Karlsson et al.
transiently expressing human or rhesus CD4, in conjunc-
tion with either human or rhesus monkey chemokine re-
ceptors. For all of the receptor combinations tested (human
CD4 and either human CXCR4 or CCR5; rhesus CD4
and either rhesus CXCR4 or CCR5), viruses with the
KB9 envelope glycoproteins were more efficient at mediat-
ing entry than were viruses with the 89.6 envelope glyco-
proteins (data not shown). Under conditions in which a
relatively brief (3-h) incubation of virus with target cells
was used, viruses with the KB9 envelope glycoproteins
were approximately threefold more efficient than viruses
with the 89.6 envelope glycoproteins. No evidence of spe-
cific adaptation to rhesus monkey receptors was observed.
Since the 89.6 envelope glycoproteins can use corecep-
tors in addition to CCR5 and CXCR4 (16, 18), the ability
of the KB9 envelope glycoproteins to use a wider panel of
seven transmembrane proteins was tested. This panel in-
cluded coreceptors that support SIV but not HIV-1 entry
(14, 44). Recombinant viruses with KB9 envelope glyco-
proteins were more efficient than viruses with the 89.6 en-
velope glycoproteins at infecting cells expressing CD4 and
the human CCR2b, CCR3, and apj proteins (data not
shown). The magnitude of this increase in efficiency was
comparable to that seen with the CCR5 and CXCR4
coreceptors. Viruses with the KB9 and 89.6 envelope gly-
coproteins did not infect cells expressing CD4 and the
known SIV coreceptors (STLR33, gpr15, and gpr1). Thus,
the changes in the KB9 envelope glycoproteins specify a
more efficient usage of several coreceptors used by the 89.6
envelope glycoproteins, but no qualitative changes in core-
ceptor usage were observed.
The increase in the efficiency with which the KB9 enve-
lope glycoproteins, compared with the 89.6 envelope gly-
coproteins, mediate infection of cells bearing specific core-
ceptors might be due to a relative increase in binding to the
coreceptors. To test this, the ability of purified 89.6 and
KB9 gp120 glycoproteins to bind human CCR5 expressed
on the surface of murine L1.2 cells was examined. An indi-
rect competition assay (19, 20) was used, since this assay
does not require iodination of the gp120 glycoproteins,
which might introduce artifactual changes in affinity for
chemokine receptors. Iodinated MIP-1b, a CCR5 ligand,
was bound to L1.2-CCR5 cells in the presence of increas-
ing concentrations of the KB9 and 89.6 gp120 glycopro-
teins. Since gp120 binding to CCR5 is greatly enhanced by
prior CD4 binding (19, 20), an excess (100 nM) of sCD4
was included in these experiments. Unlabeled MIP-1b was
included as a positive control, and the YU2DV1/2/3 pro-
tein as a negative control. The latter protein is a gp120 de-
rivative that binds CD4 efficiently but is deficient in CCR5
binding due to deletion of the V3 loop (19). Fig. 6 B shows
that, as expected, the unlabeled MIP-1b but not the
YU2DV1/2/3 protein competed for the binding of radio-
labeled MIP-1b to the L1.2-CCR5 cells. The KB9 gp120
competed more efficiently than did the 89.6 gp120. The
inhibitory (Ki) constants were 4.4 nM for the KB9 gp120
and 39.0 nM for the 89.6 gp120. Thus, the KB9 gp120 ex-
hibited an approximately ninefold apparent increase in af-
finity for CCR5 compared with the parental 89.6 gp120.
Sensitivity of SHIV Variants to Neutralization. Two of the
three in vivo passages of SHIV-89.6 that gave rise to the
pathogenic SHIV-89.6P were performed relatively late, at
12 and 14 wk after the infection (33). Therefore, some of
the passage-associated amino acid substitutions in the KB9
envelope glycoproteins may have arisen in response to im-
mune pressure from the hosts. The neutralization sensitiv-
ity of viruses with either the parental 89.6, the KB9 or the
KB9ct envelope glycoproteins was tested. Since, like most
primary HIV-1 isolates, viruses with the parental 89.6 en-
velope glycoproteins are relatively resistant to neutraliza-
tion (40), a small panel of antibodies known to neutralize the
89.6 virus was tested. These included IgG1b12, an antibody
directed against the CD4-binding site (45), and AG1121, a V3
loop–directed antibody. The sensitivity of the three viruses
to neutralization by sCD4 was also examined. As shown in
Fig. 7, viruses bearing the KB9 envelope glycoproteins
were less sensitive to neutralization by both IgG1b12 and
AG1121 antibodies, compared with viruses bearing the 89.6
or the KB9ct glycoproteins. All three viruses exhibited
comparable sensitivity to neutralization by sCD4, indicat-
ing that HIV-1 can evolve to resist antibodies directed
against receptor-binding regions of gp120 without signifi-
cantly decreasing affinity for CD4.
Antiviral Immune Responses in SHIV-infected Animals.
To characterize the antibody responses in the infected
monkeys, plasma samples from multiple time points after
infection were used to precipitate the homologous enve-
lope glycoproteins from radiolabeled COS-1 cell lysates.
The development of a strong antibody response against the
gp120 and/or gp160 envelope glycoproteins was observed
in the majority of the animals z14–17 d after inoculation
(data not shown). The monkeys with the most severe de-
cline in CD41 lymphocytes (13970, 13916, and 15431)
failed to seroconvert during the first 71 d after infection.
Figure 6. Receptor-binding of the 89.6 and KB9 gp120 envelope gly-
coproteins. (A) The binding of the 89.6 and KB9 gp120 glycoproteins to
human sCD4 absorbed onto the surface of an ELISA plate is shown. Val-
ues represent the mean and standard deviations from two independent ex-
periments, each containing four replicate samples. (B) The ability of the
89.6 and KB9 gp120 glycoproteins to compete with MIP-1b binding to
mouse cells expressing human CCR5 was assessed in the presence of 100
nM sCD4. The results shown are representative of two independent ex-
periments, each performed with duplicate samples at each concentration
of competitor. Relative inhibitory constants for MIP-1b (positive con-
trol), 89.6 gp120, and KB9 gp120 were 0.20 nM, 39.0 nM, and 4.4 nM,
respectively. The YU2DV1/2/3 glycoprotein, which lacks the V3 loop
and thus is unable to bind CCR5 (19), was included as a negative control.1168 Envelope Glycoprotein Determinants of CD41 T Cell Loss
Neutralizing activity against recombinant viruses with the
homologous envelope glycoproteins could be detected in
the plasma of most infected animals by days 22–45 after in-
oculation (data not shown). Some of the monkeys (13950
and 13945) that seroconverted did not raise neutralizing
antibodies. As expected, no neutralizing activity was de-
tected in the plasma of monkeys that failed to seroconvert.
The cytotoxic T cell responses against the 89.6 envelope
glycoproteins were assessed in four monkeys infected with
SHIV-KB9ct and four monkeys infected with SHIV-KB9.
Virus-specific cytotoxic T cell responses were measurable
in three animals (two SHIV-KB9ct–infected monkeys and
one SHIV-KB9–infected monkey) by 2 wk after inocula-
tion and in all eight animals by 3 wk after inoculation (data
not shown). There was no discernible difference in the
magnitude of the response between the two groups of ani-
mals.
Discussion
The availability of molecularly cloned SHIVs that ex-
hibit profound differences in the ability to induce CD41 T
lymphocyte loss and AIDS, while differing only moderately
in proviral sequence (34), allowed an investigation of the
molecular basis of the in vivo viral phenotypes. To this
end, it was useful to distinguish viral genetic determinants
of in vivo replicative ability from those viral elements that
influence intrinsic pathogenicity, i.e., CD41 T lympho-
cyte–depleting capacity. The rather modest differences in
levels of viremia between the pathogenic SHIV-89.6P vi-
rus and the parental virus SHIV-89.6, combined with the
large variation in virus replication in different monkeys in-
oculated with the identical virus, suggested that genetic de-
terminants of both replication and intrinsic pathogenicity
were operative in this system and could be defined.
In the pathogenic SHIV-KB9, changes both in the enve-
lope glycoprotein ectodomains and cytoplasmic tail con-
tributed to modest and additive increases in virus replica-
tion during the first weeks of infection in vivo. The
envelope glycoprotein ectodomain changes associated with
the pathogenic virus specify an increase in virus replication
in cultured rhesus monkey PBMC. This increase is re-
flected in an increase in the efficiency with which the
chemokine receptors used by the parental SHIV-89.6 virus
are used by SHIV-KB9. No qualitative changes in chemokine
receptor usage were observed between SHIV-89.6 and
SHIV-KB9. At least part of the increased efficiency of virus
entry associated with the SHIV-KB9 envelope glycopro-
tein ectodomains can be attributed to an increase in the af-
finity of gp120–CD4 complexes for the chemokine recep-
tors. Although we could document this increased affinity in
the only available quantitative binding assay, which uses
CCR5 as a target (19), the increased efficiency of SHIV-
KB9 entry into target cells expressing CXCR4, CCR3,
and CCR2b raises the possibility that the KB9 gp120 ex-
hibits an increased affinity for other coreceptors besides
CCR5.
The gp41 cytoplasmic tail change associated with the
pathogenic SHIV-KB9 is dramatic, involving the replace-
ment of HIV-1 envelope glycoprotein sequences with
those of SIV (34). This change apparently contributes to vi-
rus replication in vivo, and to modest increases in replica-
tion in cultured rhesus monkey PBMCs. The basis for
these increases is uncertain. One obvious possibility is that
the modified KB9 gp41 cytoplasmic tail is more compatible
with the SIV matrix protein in the SHIV chimera. In vi-
ruses produced in CEM3174 cells, we did not observe any
difference in the efficiency with which envelope glycopro-
teins containing KB9 cytoplasmic tails were incorporated
into SHIV virions (Karlsson, G., and J. Sodroski, unpub-
lished observations), an expected consequence of improved
matrix–gp41 compatibility. It remains possible that such
phenotypes are subtle and/or dependent on the virus-pro-
ducing cell types.
The risk of clinical sequelae of HIV-1 infection in hu-
mans is highly dependent upon the absolute CD41 T lym-
phocyte levels (46, 47). Likewise, SHIV-infected monkeys
that develop AIDS-like illness and die within 12 mo of in-
fection uniformly exhibit rapid and profound decreases in
the number of CD41 T lymphocytes in the peripheral blood
and tissues in the first 3 wk after infection (33). Our results
demonstrate that the structure of the SHIV envelope gly-
coprotein ectodomains determines the efficiency of CD41
T lymphocyte depletion, beyond any effects on the overall
pattern or level of viremia. Thus, HIV-1 envelope glyco-
protein ectodomain sequences can apparently influence the
intrinsic pathogenicity of SHIVs. In this study we identified
two properties specified by the KB9 ectodomain se-
quences: an increase in membrane fusogenic capacity and a
decreased sensitivity to antibody neutralization. The in-
crease in fusogenic activity is probably closely related to the
increase in virus entry discussed above and is at least in part
a result of increased chemokine receptor binding. That
Figure 7. Neutralization of vi-
ruses with the 89.6, KB9ct and
KB9 envelope glycoproteins. Re-
combinant viruses encoding CAT
and bearing either the 89.6,
KB9ct, or KB9 envelope glyco-
proteins were incubated with dif-
ferent concentrations of IgG1b12
(A), AG1121 (B), or sCD4 (C).
The viruses were then incubated with CEM3174 cells. CAT activity in
the CEM3174 cells was assessed 3 d later and is expressed as the percent-
age of CAT activity seen in the absence of antibody or sCD4. The results
shown are representative of those obtained in at least two independent
experiments.1169 Karlsson et al.
more fusogenic envelope glycoprotein ectodomains arose
in conjunction with the generation of a virus with im-
proved capability of depleting CD41 T lymphocytes in
vivo is intriguing. The ability of the HIV-1 envelope gly-
coproteins to mediate membrane fusion has been strongly
associated with both forms of viral cytopathic effects, single
cell lysis and syncytium formation (8, 9, 11). Thus, at least
in tissue culture systems, both the destruction of the in-
fected cell and of receptor-bearing, uninfected cells is de-
pendent on the efficiency with which the HIV-1 envelope
glycoproteins fuse membranes.
Further work will be required to define precisely the
mechanisms by which the envelope glycoprotein ecto-
domains modulate the efficiency of CD41 T cell depletion.
An understanding of pathogenic mechanisms in the SHIV-
macaque model would benefit from knowledge of the
relative involvement of infected and uninfected CD41 T
lymphocytes in T cell loss. Based on the resolution of the
antigenemia, the average in vivo life span of cells producing
any of the SHIV variants must be ,3–4 d, consistent with
values observed in HIV-1–infected humans and SIV-infected
monkeys (6, 7, 48). Thus, although envelope glycoprotein
ectodomain sequences could influence the rate of infected
cell destruction, the eventual outcome of infection and
virus production is cell death. This is consistent with the
observation that all of the SHIV variants used in this study
retain some degree of cytopathic potential and can elicit cyto-
toxic T cells, which will eventually destroy virus-producing
cells not eliminated by viral killing mechanisms.
Our observation that similar degrees of CD4 T lympho-
cyte depletion occur in animals with a wide range of viral
RNA–positive cells in the lymph nodes suggests that unin-
fected CD41 T lymphocytes are destroyed in some SHIV-
infected monkeys. If so, our data imply that a direct or in-
direct interaction with virus-producing cells drives this
process or, if free virions contribute, that the envelope gly-
coprotein ectodomain sequences determine the efficiency
of cell killing. A potentially relevant observation is that
even when comparable numbers of viral RNA-positive
cells were present in the lymph nodes, an animal (13930)
infected with a KB9 ectodomain-containing virus exhib-
ited much lower CD41 T lymphocyte counts than animals
(15655 and 18431) infected with viruses containing wild-
type 89.6 ectodomains (Fig. 4). Perhaps under conditions
where only low percentages of CD41 T lymphocytes are
infected, as in this example, the increased potential of en-
velope glycoproteins containing KB9 ectodomains to me-
diate the destruction of uninfected cells is manifest.
Since envelope glycoprotein structure could influence
the generation of immune responses that might modulate
the longevity of the infected cell, the cytotoxic T cell and
antibody responses to the envelope glycoproteins in SHIV-
infected animals were examined. The efficiencies with
which Env-specific cytotoxic T lymphocytes were gener-
ated did not significantly differ among animals infected
with SHIV variants differing in the envelope glycoprotein
ectodomains. Since more monkeys infected with SHIVs
containing the KB9 envelope glycoprotein ectodomains
exhibited lower CD41 lymphocyte counts, neutralizing
antibody responses in this group were in some cases de-
layed or undetectable. Thus, an increase in the efficiency
with which the envelope glycoproteins with KB9 ecto-
domains elicit immune responses is not the explanation for
the in vivo properties related to CD41 lymphocyte de-
struction specified by these sequences.
SHIVs with the KB9 envelope glycoprotein ectodomains
are more resistant to neutralizing antibodies than are viruses
with the wild-type 89.6 ectodomains. Although this ecto-
domain-specified property is likely to be important for the
maintenance of a chronic infection and eventual disease in-
duction, it seems less likely to contribute to the efficiency
of acute CD41 T lymphocyte depletion. Antibodies directed
against the viral envelope glycoprotein were not detectable
in the SHIV-infected monkey plasma until 2–3 wk after in-
fection, after the course of CD41 T lymphocyte decline was
established. Neutralizing antibodies were not detected in any
of the animals until well after CD41 lymphocyte counts had
reached their nadir. In monkeys exhibiting the greatest
CD41 T lymphocyte decline, virus-specific antibody re-
sponses were delayed or, in some cases, undetectable.
The studies reported herein implicate the HIV-1 exterior
envelope glycoprotein domains in determining the effi-
ciency of CD41 T lymphocyte destruction in SHIV-89.6P–
infected monkeys. These ectodomain sequences modulate
the relationship between virus load and CD41 T lympho-
cyte numbers in a manner distinct from that seen for viral
sequences (e.g., the gp41 cytoplasmic tail) that influence
only virus replication. This model system and approach
could be used to address the contribution of other HIV-1 or
SIV genes to CD41 T lymphocyte destruction. A definition
of genetic determinants of intrinsic pathogenicity is the
foundation for an understanding of pathogenic mechanisms.
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